<DOC>
	<DOCNO>NCT00003913</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Umbilical cord blood transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill cancer cell . PURPOSE : Phase II trial study effectiveness umbilical cord blood transplantation plus combination chemotherapy treat patient hematologic cancer nonmalignant hematologic disease .</brief_summary>
	<brief_title>Umbilical Cord Blood Transplantation Treating Patients With Hematologic Cancer Nonmalignant Hematologic Disease</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy umbilical cord blood transplantation , measure durable neutrophil engraftment , patient malignant nonmalignant hematological disease . - Determine disease-free survival long-term survival patient treat regimen . - Determine incidence neutrophil engraftment , primary secondary graft failure , platelet engraftment , RBC engraftment patient treat regimen . - Determine incidence severity acute chronic graft-versus-host disease , complication ( infection , veno-occlusive disease , interstitial pneumonitis ) , relapse , malignancy , lymphoproliferative disorder , posttransplantation myelodysplasia patient treat regimen . - Determine immune reconstitution patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord disease group ( malignant v nonmalignant ) . Patients malignant disease stratify accord quality HLA match ( 1 2/6 v 3/6 v 4/6 v 5/6 6/6 ) , cell dose , age . Patients assign one three conditioning regimen , depend disease . - Group A ( malignant disease ) : Patients undergo total body irradiation ( TBI ) day -8 twice daily day -7 -4 . Male patient acute lymphocytic leukemia ( ALL ) undergo radiotherapy boost testis . Patients receive cyclophosphamide ( CTX ) IV day -3 -2 methylprednisolone ( MePRDL ) IV anti-thymocyte globulin ( ATG ) IV day -3 -1 . - Group B ( inborn error metabolism/storage disease ) : Patients receive oral busulfan ( BU ) every 6 hour day -6 -5 , CTX IV day -4 -3 , MePRDL IV ATG IV every 12 hour day -2 -1 . - Group C ( nonmalignant disease ) : Patients receive oral BU every 6 hour day -9 -6 , CTX IV day -5 -2 , MePRDL IV ATG IV day -3 -1 . Patients group receive cord blood IV maximum 30 minute day 0 . Patients also receive MePRDL IV first half infusion administer immediately cord blood infusion filgrastim ( G-CSF ) IV begin 4 hour transplantation continue blood count recover . Patients follow 30 , 60 , 90 day ; 6 month ; annually thereafter . PROJECTED ACCRUAL : Approximately 390 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow diagnosis : Acute myeloid leukemia ( AML ) , without myelodysplastic syndrome Not first complete remission ( CR ) * translocation ( 8 ; 21 ) inv ( 16 ) unless failure firstline induction therapy Not first CR* translocation ( 15 ; 17 ) abnormality unless : Failure firstline induction therapy OR Molecular evidence persistent disease Not first CR Down syndrome Patients third great medullary relapse refractory disease ( primary induction failure ) receive busulfan/melphalan condition regimen NOTE : * CR define great 5 % blast marrow Acute lymphocytic leukemia ( ALL ) Not first CR OR Highrisk ALL first CR , high risk define one following : Hypoploidy ( great 44 chromosome ) Pseudodiploidy translocation molecular evidence ( 9 ; 22 ) , 11q23 , ( 8 ; 14 ) ( except Bcell ALL ) without MLL gene arrangement Elevated WBC presentation Age 612 month : great 100,000/mm^3 Age 1017 year : great 200,000/mm^3 Age 18 : great 20,000/mm^3 Failed achieve CR 4 week induction therapy Patients BALL must first CR , must meet least one highrisk criterion specify , must meet following criterion : Translocation ( 8 ; 14 ) Blasts surface immunoglobulin CD10 positive Patients third great medullary relapse refractory disease ( primary induction failure ) receive busulfan/melphalan condition regimen Chronic myelogenous leukemia , meet criterion 1 follow : Accelerated phase Chronic phase 1 year diagnosis without match unrelated bone marrow donor AND unresponsive unable tolerate interferon Blast crisis , define great 30 % promyelocytes plus blast bone marrow Patients receive busulfan/melphalan condition regimen Acute undifferentiated leukemia ( AUL ) , infant leukemia , biphenotypic leukemia Patients third great medullary relapse refractory disease ( primary induction failure ) receive busulfan/melphalan condition regimen Juvenile myelomonocytic leukemia meeting follow criterion : No Philadelphia chromosome Bone marrow blast less 30 % Peripheral blood monocyte great 1,000/mm^3 At least 2 follow : Peripheral blood spontaneous growth and/or sargramostim ( GMCSF ) hypersensitivity Increased hemoglobin F age Clonal abnormality ( e.g. , monosomy 7 RAS mutation ) Peripheral blood myeloid precursor WBC great 10,000/mm^3 Myelodysplastic syndrome define follow : Refractory anemia ( RA ) RA ring sideroblast RA excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia Paroxysmal nocturnal hemoglobinuria Hodgkin 's lymphoma nonHodgkin 's lymphoma beyond first CR primary induction failure AND chemosensitive ( great 50 % reduction tumor mass size ) Inborn error metabolism include , limited , Hurler 's syndrome , adrenoleukodystrophy ( ALD ) , MaroteauxLamy syndrome , globoid cell leukodystrophy , metachromatic leukodystrophy , fucosidosis , mannosidosis For ALD patient age 5 , IQ must least 80 For patient age 5 , IQ must least 70 For patient age 5 , developmental quotient clinical neurodevelopmental examination demonstrate potential stabilization level function continuous life support ( e.g. , mechanical ventilation ) would predict required year transplantation Combined immune deficiency include , limited : Severe combine immunodeficiency ( SCID ) require cytoreduction WiskottAldrich syndrome Leukocyte adhesion defect ChediakHigashi disease Xlinked lymphoproliferative disease Adenosine deaminase deficiency Purine nucleoside phosphorylase deficiency Xlinked SCID Common variable immune deficiency Nezelof 's syndrome Cartilage hair hypoplasia No dyskeratosis congenita No ALL , AML , AUL , biphenotypic leukemia third high medullary relapse refractory disease primary induction failure No primary myelofibrosis myelofibrosis grade 3 bad No active CNS leukemia involvement ( CSF WBC great 5/mm^3 malignant cell cytospin ) No consent 5/6 6/6 HLAmatched relate donor available 36/6 HLAmatched unrelated umbilical cord blood donor available PATIENT CHARACTERISTICS : Age : See Disease Characteristics 18 Performance status : Karnofsky 70100 % , age 16 18 Lansky 50100 % , age 16 Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin le 2.5 mg/dL SGOT le 5 time upper limit normal Renal : Creatinine normal age OR Creatinine clearance glomerular filtration rate great 50 % low limit normal age Cardiovascular : If symptomatic : LVEF great 40 % ( shorten fraction great 26 % ) improve exercise OR Shortening fraction great 26 % Pulmonary : If symptomatic : DLCO , FEV_1 , FEC great 45 % predict OR Oxygen saturation great 85 % room air Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No uncontrolled viral , bacterial , fungal infection PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 1 year since prior allogeneic stem cell transplantation ( SCT ) cytoreductive preparative therapy At least 6 month since prior autologous SCT No concurrent thrombopoietic growth factor Chemotherapy : See Disease Characteristics See Biologic therapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
</DOC>